Johnson & Johnson vs Merck & Co.: Business Model & Financial Comparison 2026
Johnson & Johnson · Healthcare / Drug Manufacturers - General·Merck & Co. · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | JNJJohnson & Johnson | MRKMerck & Co. |
|---|---|---|
| Market Cap | $582.04B | $285.83B |
| Revenue (TTM) | $94.19B | $65.01B |
| Revenue Growth | 9.1% | 5.0% |
| Gross Margin | 68.1% | 77.2% |
| Operating Margin | 24.0% | 32.8% |
| Net Margin | 28.5% | 28.1% |
| Return on Equity | 35.0% | 36.9% |
| P/E (Trailing) | 21.9x | 15.9x |
| P/E (Forward) | 19.2x | 11.8x |
| Free Cash Flow | $16.63B | $11.89B |
| Cash | $20.10B | $14.57B |
| Total Debt | $49.33B | $50.53B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Johnson & Johnson
Johnson & Johnson stands as a leading company in Healthcare. Generating $94.19 billion in annual revenue (growing 9.1% year-over-year) and carrying a market capitalization of $577.48 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Johnson & Johnson continues to execute on a multi-year strategic vision that balances growth inv…
Full Johnson & Johnson analysis →Merck & Co.
Merck & Co., Inc. stands as a leading company in Healthcare. Generating $65.01 billion in annual revenue (growing 5.0% year-over-year) and carrying a market capitalization of $286.97 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Merck & Co., Inc. continues to execute on a multi-year strategic vision that balances growth inv…
Full Merck & Co. analysis →SWOT Analysis Comparison
Strengths
Johnson & Johnson
- With a market capitalization of $577.48B, Johnson & Johnson is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access th
- Johnson & Johnson's gross margin of 68.1% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 24.0% demonstrates dis
- A return on equity of 35.0% demonstrates that Johnson & Johnson generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Merck & Co.
- With a market capitalization of $286.97B, Merck & Co., Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access th
- Merck & Co., Inc.'s gross margin of 77.2% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 32.8% demonstrates dis
- A return on equity of 36.9% demonstrates that Merck & Co., Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Weaknesses
Johnson & Johnson
- Johnson & Johnson's debt-to-equity ratio of 60.5 indicates meaningful financial leverage. Total debt stands at $49.33B against $20.10B in cash and equivalents.
- With 138,200 employees globally, Johnson & Johnson faces inherent challenges in agility, decision-making speed, and maintaining a consistent culture across geographies — advantages that smaller, nimbl
Merck & Co.
- Merck & Co., Inc.'s debt-to-equity ratio of 96.0 indicates meaningful financial leverage. Total debt stands at $50.53B against $14.57B in cash and equivalents.
Opportunities
Johnson & Johnson
- Johnson & Johnson operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in th
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Johnson
- Earnings growth of 48.6% YoY demonstrates Johnson & Johnson's ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage as fi
Merck & Co.
- Merck & Co., Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in th
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Merck &
- With $14.57B in cash and strong free cash flow generation, Merck & Co., Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Threats
Johnson & Johnson
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Johnson & Johnson's revenue is not fully insulated from macroeconomic cycles, and a recessio
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Johnson & Johnson's
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Merck & Co.
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Merck & Co., Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recessio
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Merck & Co., Inc.'s
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolJohnson & Johnson vs Merck & Co.: FAQ
- Is Johnson & Johnson bigger than Merck & Co.?
- By market capitalization, Johnson & Johnson is larger at $582.04B vs Merck & Co.'s $285.83B.
- Which has better profit margins — Johnson & Johnson or Merck & Co.?
- Johnson & Johnson has higher net profit margins (28.5%) compared to Merck & Co. (28.1%). Gross and operating margins are compared in the table above.
- What sectors do Johnson & Johnson and Merck & Co. operate in?
- Johnson & Johnson operates in the Healthcare sector (Drug Manufacturers - General). Merck & Co. operates in the Healthcare sector (Drug Manufacturers - General).
- How does Johnson & Johnson's revenue compare to Merck & Co.'s?
- Johnson & Johnson generates $94.19B in annual revenue (TTM) while Merck & Co. generates $65.01B. Johnson & Johnson is the larger company by revenue as of 2026.